In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

Virology

Volumn 351, Issue 2, 2006, Pages 349-359

  Le Pogam, Sophie ^a   Jiang, Wen Rong ^a   Leveque, Vincent ^a   Rajyaguru, Sonal ^a   Ma, Han ^a   Kang, Hyunsoon ^a   Jiang, Sharon ^a   Singer, Margaret ^a   Ali, Samir ^a   Klumpp, Klaus ^a   Smith, Dave ^a   Symons, Julian ^a   Cammack, Nick ^a   Nájera, Isabel ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Combination therapy; Drug resistance; Hepatitis C virus; Inhibitors; NS5B polymerase; Nucleoside analogs; Treatment

Indexed keywords

ADENOSINE DERIVATIVE; ALPHA2A INTERFERON; AMINO ACID; ANTIVIRUS AGENT; CYTIDINE DERIVATIVE; RECOMBINANT ALPHA2A INTERFERON; RNA; THIOPHENE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG INHIBITION; DRUG POTENCY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REPLICON; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CELL LINE; CYTIDINE; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; MOLECULAR STRUCTURE; RNA, VIRAL; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 33744910421     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.03.045     Document Type: Article

References (32)

1. Beaulieu P.L., Bos M., Bousquet Y., DeRoy P., Fazal G., Gauthier J., Gillard J., Goulet S., McKercher G., Poupart M.A., Valois S., and Kukolj G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 14 4 (2004) 967-971
2. Beaulieu P.L., Bos M., Bousquet Y., Fazal G., Gauthier J., Gillard J., Goulet S., LaPlante S., Poupart M.A., Lefebvre S., McKercher G., Pellerin C., Austel V., and Kukolj G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives. Bioorg. Med. Chem. Lett. 14 1 (2004) 119-124
3. Beaulieu P.L., Bousquet Y., Gauthier J., Gillard J., Marquis M., McKercher G., Pellerin C., Valois S., and Kukolj G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J. Med. Chem. 47 27 (2004) 6884-6892
4. Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L., Mathieu M., De Francesco R., and Rey F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 96 23 (1999) 13034-13039
5. Carroll S.S., Tomassini J.E., Bosserman M., Getty K., Stahlhut M.W., Eldrup A.B., Bhat B., Hall D., Simcoe A.L., LaFemina R., Rutkowski C.A., Wolanski B., Yang Z., Migliaccio G., De Francesco R., Kuo L.C., MacCoss M., and Olsen D.B. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278 14 (2003) 11979-11984
6. Chan L., Das S.K., Reddy T.J., Poisson C., Proulx M., Pereira O., Courchesne M., Roy C., Wang W., Siddiqui A., Yannopoulos C.G., Nguyen-Ba N., Labrecque D., Bethell R., Hamel M., Courtemanche-Asselin P., L'Heureux L., David M., Nicolas O., Brunette S., Bilimoria D., and Bedard J. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication: Part 1. Sulfonamides. Bioorg. Med. Chem. Lett. 14 3 (2004) 793-796
7. Chan L., Pereira O., Reddy T.J., Das S.K., Poisson C., Courchesne M., Proulx M., Siddiqui A., Yannopoulos C.G., Nguyen-Ba N., Roy C., Nasturica D., Moinet C., Bethell R., Hamel M., L'Heureux L., David M., Nicolas O., Courtemanche-Asselin P., Brunette S., Bilimoria D., and Bedard J. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication: Part 2. Tertiary amides. Bioorg. Med. Chem. Lett. 14 3 (2004) 797-800
8. Dhanak D., Duffy K.J., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.Y., Chan G., Khandekar S., Keenan R.M., and Sarisky R.T. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277 41 (2002) 38322-38327
9. Elion G.B., Singer S., and Hitchings G.H. Antagonists of nucleic acid derivatives. J. Biol. Chem. 208 (1954) 477-488
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 13 (2002) 975-982
11. Godofsky E.W., Afdhal N., Rustgi V., Shick L., Duncan L., Zhou X.L., Chao G., Fang C., Fielman B., Myers M., and Brown N.A. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity on NM283, a novel antiviral treatment for hepatitis C. Gastroenterology 126 4 Suppl. 2 (2004) 407
12. Gu B., Gates A.T., Isken O., Behrens S.-V., and Sarisky R.T. Replication studies using genotype 1a subgenomic hepatitis C virus replicons. J. Virol. 77 9 (2003) 5352-5359
13. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr. H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., and Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 5 (2004) 346-355
14. Klumpp K., Leveque V., Le Pogam S., Ma H., Jiang W., Kang H., Granycome C., Singer M., Laxton C., Hang J.Q., Sarma K., Smith D.B., Heindl D., Hobbs C.J., Merrett J.H., Symons J., Cammack N., Martin J.A., Devos R., and Najera I. The novel nucleoside analog R1479 (4′-Azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281 7 (2006) 3793-3799
15. Krieger N., Lohmann V., and Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75 10 (2001) 4614-4624
16. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 5424 (1999) 110-113
17. Lohmann V., Hoffmann S., Herian U., Penin F., and Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77 5 (2003) 3007-3019
18. Ludmerer S.W., Graham D.J., Boots E., Murray E.M., Simcoe A., Markel E.J., Grobler J.A., Flores O.A., Olsen D.B., Hazuda D.J., and LaFemina R.L. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49 5 (2005) 2059-2069
19. Ma H., Leveque V., De Witte A., Li W., Hendricks T., Clausen S.M., Cammack N., and Klumpp K. Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 332 1 (2005) 8-15
20. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
21. Migliaccio G., Tomassini J.E., Carroll S.S., Tomei L., Altamura S., Bhat B., Bartholomew L., Bosserman M.R., Ceccacci A., Colwell L.F., Cortese R., De Francesco R., Eldrup A.B., Getty K.L., Hou X.S., LaFemina R.L., Ludmerer S.W., MacCoss M., McMasters D.R., Stahlhut M.W., Olsen D.B., Hazuda D.J., and Flores O.A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278 49 (2003) 49164-49170
22. Nguyen T.T., Gates A.T., Gutshall L.L., Johnston V.K., Gu B., Duffy K.J., and Sarisky R.T. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47 11 (2003) 3525-3530
23. Olsen D.B., Eldrup A.B., Bartholomew L., Bhat B., Bosserman M.R., Ceccacci A., Colwell L.F., Fay J.F., Flores O.A., Getty K.L., Grobler J.A., LaFemina R.L., Markel E.J., Migliaccio G., Prhavc M., Stahlhut M.W., Tomassini J.E., MacCoss M., Hazuda D.J., and Carroll S.S. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48 10 (2004) 3944-3953
24. Pierra C., Benzaria S., Amador A., Moussa A., Mathieu S., and Gosselin G. NM283, an efficient prodrug of the potent anti-HCV agent 2′-C-Methylcytidine. Nucleosides Nucleotides Nucleic Acids 24 (2005) 767-770
25. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., and Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75 3 (2001) 1252-1264
26. Prichard M.N., and Shipman C.J. A three-dimensional model to analyze drug-drug interactions. Antiviral. Res. 14 (1990) 181-206
27. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85 Pt. 11 (2004) 3173-3188
28. Smith R.M., Walton C.M., Wu C.H., and Wu G.Y. Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences. J. Virol. 76 19 (2002) 9563-9574
29. Tomei L., Altamura S., Bartholomew L., Biroccio A., Ceccacci A., Pacini L., Narjes F., Gennari N., Bisbocci M., Incitti I., Orsatti L., Harper S., Stansfield I., Rowley M., De Francesco R., and Migliaccio G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77 24 (2003) 13225-13231
30. Tomei L., Altamura S., Bartholomew L., Bisbocci M., Bailey C., Bosserman M., Cellucci A., Forte E., Incitti I., Orsatti L., Koch U., De Francesco R., Olsen D.B., Carroll S.S., and Migliaccio G. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78 2 (2004) 938-946
31. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20 1 (2000) 1-16
32. Yi M., and Lemon S.M. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 78 (2004) 7904-7915